M&A Deal Summary |
|
|---|---|
| Date | 2016-11-15 |
| Target | AMEGABIOTECH - Interferon Alpha Manufacturing Technology |
| Sector | Life Science |
| Buyer(s) | Neovacs |
| Sellers(s) | Amega Biotech |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1993 |
| Sector | Life Science |
| Employees | 20 |
| Revenue | 5M EUR (2013) |
Neovacs a spin-off from Pierre & Marie Curie University, Paris, France, is a biotechnology company acknowledged as a pioneer in the development of proprietary immunotherapeutics for autoimmune and chronic diseases. Neovacs was founded in 1993 and is based in Paris, France.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Argentina M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
Amega Biotech is a developer of of biotech products for human health - located in Argentina. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer. Their work and vision are directed forward.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Argentina M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
